medigraphic.com
ISSN 0188-2198 (Impreso)

2001, Número 1

<< Anterior Siguiente >>

Rev Mex Cardiol 2001; 12 (1)


Tratamiento

Cardona MEG, Carranza MJ, Hernández HH

Idioma: Español
Referencias bibliográficas: 35
Paginas: 25-36
Archivo PDF: 191.48 Kb.


FRAGMENTO

OBJETIVO

El objetivo del tratamiento, es evitar o reducir la mortalidad y las complicaciones que causa la enfermedad, con incremento en la duración de la vida y mantenimiento de una alta calidad de la misma. Hay correlación entre estos objetivos con la disminución de las cifras tensionales, lo que nos sirve como indicador de que estamos llevando un correcto plan terapéutico. Lo podemos dividir en dos grandes grupos, las modificaciones del estilo de vida y el empleo de fármacos antihipertensivos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.

  2. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertension 1999; 17: 151-183.

  3. Proyecto de Norma Oficial Mexicana para la Prevención, Tratamiento y Control de la Hipertensión Arterial. Subsecretaría de Prevención y Control de Enfermedades, Coordinación de Vigilancia Epidemiológica, Secretaría de Salud. Enero de 1999.

  4. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principals results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.

  5. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al, for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29: 641-650.

  6. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-Stage renal disease in African-american and white men: 16-year MRFIT findings. JAMA 1997; 277: 1293-1298.

  7. Hansson L, Lindholm LH, Niskanen L et al, for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.

  8. Julius S. The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Clin Exp Hypertension 1996; 18: 305-321.

  9. Carranza J, Chávez F, Huape S, Moreno A, Lázaro A, Herrera JE. Eficacia de diuréticos, betabloqueadores, inhibidores de la ECA y calcio antagonistas en el tratamiento de la hipertensión arterial esencial. Memorias del XVII Congreso Nacional de Farmacología, San Luis Potosí, SLP, 1995: 41.

  10. Burnett Jr JC. Vasopeptidade inhibition: a new concept in blood pressure management. J Hypertens 1999; 17(suppl 1): S37-S43.

  11. Amery A, Birkenhäger WH, Bulpitt CJ, Dollery CT. European Working Party on High blood pressure in the Elderly. Am J Med 1991-90; (suppl 3ª): 1S-64S.

  12. Staessen JA, Fagard R, Thijs L et al. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med 1998; 158; 1681-1691.

  13. Wang JG, Liu G, Wang X, Zhang S, Sun M, Pan X, Jian M, Gong L, Thijs L, Staessen J, Fagard R, Liu L. Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens 1996; 10: 735-742.

  14. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatments in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.

  15. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. JAMA 1988; 259: 2118-2122.

  16. Gottdiener JS, Reda DJ, Massie BM, Matterson BJ, for the Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1997; 95: 2007-2014.

  17. Vanhoutte PM, Lüscher T. Role of endothelium in the pathophysiology of hypertension. JAMA 1988; 4(suppl 4): 34.

  18. Doughty R, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997; 18: 560- 565.

  19. Carranza MJ, Lázaro CA, Chávez CF, Huape AS, Moreno RA, Herrera JE. El estudio: The Hypertension Optimal Treatment (HOT). Datos internacionales del primer año y locales a dos años. Memorias del 5º Congreso Nacional de la Sociedad de Hipertensión Arterial de México A. C., México D.F., de 1996.

  20. Pollare T, Lithell H, Berne C. A comparison of the effect of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 211: 868-873.

  21. Mancini GB, Henry GC, Macaya C, O’Neill BJ, Pucillo AL, Carere RG et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor disjunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-265.

  22. Lüscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal. Drugs 1998; 55: 509-517.

  23. Tuomilehto J, Rastenyte D, Birkenhäger WH et al. For the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-684.

  24. Hoyo-Vadillo C, Castañeda-Hernández G, Herrera JE, Vidal-Gárate J, Moreno-Ramos A, Chávez F, Hong E. Pharmacokinetics on nifedipine slow release tablet in Mexican subjects: Further evidence for an oxidation polymorphism. J Clin Pharmacol 1989; 29: 816-820.

  25. Carranza J, Coria MA, Huape S, Lázaro A, Chávez F. Curso temporal del efecto antihipertensivo de los dihidropiridínicos en hipertensos esenciales mexicanos. Memorias del XXI Congreso Nacional de Medicina Interna, Monterrey, NL, 1998: 67.

  26. Taddei S, Virdis A, Ghiadoni L, Sudano I, Noll G, Lüscher TF et al. Nifedipine enhances endothelium-dependent relaxations and inhibits contractions to endothelin-1 and phenilephrine in human hypertension (abstract). Circulation 1997; 96(suppl 1): 762-763.

  27. Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilatation in essential hypertensive patients. Hypertension 1997; 30: 1606-1612.

  28. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276: 1328-1331.

  29. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: A new approach to blockade of renin-angiotensin system. Am Heart J 1994; 12: 79-87.

  30. Kassler-Taub K, Littlejohn T, Elliot W, Ruddy T, Adler E. Comparative efficay of angiotensin II receptors antagonists irbesartan and losartan in mild and moderate hypertension. Am J Hypertens 1998; 11: 445-453.

  31. Jover B, Mimran A. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function. J Hypertens 1994; 12(suppl 9): 3-9.

  32. Alvarado-Jiménez MR, Carranza-Madrigal J, Rodríguez-Barrón A, Chávez-Carbajal F, Huape-Arreola S, Rodríguez-Saldaña J, Acevedo-Venegas G. Efecto del irbesartan sobre la presión arterial y la excreción urinaria de albúmina en el Programa de Evidencias Cardiovasculares 3 (PECAV-3). Memorias del XXII Congreso Nacional de Medicina Interna, Guadalajara, Jal., 1999: 245.

  33. Menard J, Chatellier G, Azizi M. Do we need angiotensin II antagonists to treat hypertensive patients? J Hum Hypertens 1997; 11 (suppl 2): 1-7.

  34. Pitt B, Segal R, Martínez FA, Meurers G, Cowley AJ, Thomas I et al, on behalf ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure evaluation of Losartan in the Elderly Study, ELITE. Lancet 1997; 349: 747-752.

  35. Goldberg MR, Bradstreet TE, McWilliams EJ et al. Biochemical effects on losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25: 37-46.




2020     |     www.medigraphic.com